Bitter melon (Momordica charantia) extract suppresses adrenocortical cancer cell proliferation through modulation of the apoptotic pathway, steroidogenesis, and insulin-like growth factor type 1 receptor/RAC-α serine/threonine-protein kinase signaling

Journal of Medicinal Food

Volumn 15, Issue 4, 2012, Pages 325-334

  Brennan, Victoria C ^a   Wang, Chiung Min ^a   Yang, Wei Hsiung ^a  

^a MERCER UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

adrenocortical cancer; apoptosis; bitter melon; insulin like growth factor 1 receptor; steroidogenesis

Indexed keywords

CASPASE 3; CYCLIN D1; CYCLIN D2; CYCLIN D3; CYCLIN DEPENDENT KINASE 7; CYCLIN DEPENDENT KINASE INHIBITOR 1A; MOMORDICA CHARANTIA EXTRACT; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PROTEIN KINASE; PROTEIN P53; SOMATOMEDIN C RECEPTOR; STRESS ACTIVATED PROTEIN KINASE 1; THREONINE; TRANSCRIPTION FACTOR 3;

ADRENAL CANCER; ANIMAL CELL; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; CELL CYCLE REGULATION; CELL PROLIFERATION; CELL SURVIVAL; DOSE RESPONSE; DRUG EFFICACY; ENZYME ACTIVATION; HUMAN; HUMAN CELL; IN VITRO STUDY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN CLEAVAGE; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; STEROIDOGENESIS;

ADRENOCORTICAL CARCINOMA; ANIMALS; APOPTOSIS; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; CYCLIN-DEPENDENT KINASE INHIBITOR P21; HUMANS; MALE; MICE; MITOGEN-ACTIVATED PROTEIN KINASE 8; MOMORDICA CHARANTIA; PHOSPHORYLATION; PLANT EXTRACTS; RATS; RATS, SPRAGUE-DAWLEY; RECEPTOR, IGF TYPE 1; SIGNAL TRANSDUCTION;

CUCUMIS; CUCURBITA PEPO VAR. MELOPEPO; CUCURBITA PEPO VAR. OVIFERA; MOMORDICA CHARANTIA; VACCINIUM;

EID: 84859061077     PISSN: 1096620X     EISSN: 15577600     Source Type: Journal    
DOI: 10.1089/jmf.2011.0158     Document Type: Article

References (43)

1. Wajchenberg BL, Albergaria Pereira MA, Medonca BB, Latronico AC, Campos Carneiro P, Alves VA, Zerbini MC, Liberman B, Carlos Gomes G, Kirschner MA: Adrenocortical carcinoma: clinical and laboratory observations. Cancer 2000; 88:711-736.
2. Allolio B, Fassnacht M: Clinical review: adrenocortical carcinoma: clinical update. J Clin Endocrinol Metab 2006;91:2027-2037.
3. Cazejust J, De Baère T, Auperin A, Deschamps F, Hechelhammer L, Abdel-Rehim M, Schlumberger M, Leboulleux S, Baudin E: Transcatheter arterial chemoembolization for liver metastases in patients with adrenocortical carcinoma. J Vasc Interv Radiol 2010;21:1527-1532.
4. Almeida MQ, Fragoso MC, Lotfi CF, Santos MG, Nishi MY, Costa MH, Lerario AM, Maciel CC, Mattos GE, Jorge AA, Mendonca BB, Latronico AC: Expression of insulin-like growth factor-II and its receptor in pediatric and adult adrenocortical tumors. J Clin Endocrinol Metab 2008;93:3524-3531.
5. Barlaskar FM, Spalding AC, Heaton JH, Kuick R, Kim AC, Thomas DG, Giordano TJ, Ben-Josef E, Hammer GD: Preclinical targeting of the type I insulin-like growth factor receptor in adrenocortical carcinoma. J Clin Endocrinol Metab 2009;94:204-212.
6. Jassim SA, Naji MA: Novel antiviral agents: a medicinal plant perspective. J Appl Microbiol 2003;95:412-427.
7. Grover JK, Yadav S, Vats V: Medicinal plants of India with antidiabetic potential. J Ethnopharmacol 2002;81:81-100.
8. Leung L, Birtwhistle R, Kotecha J, Hannah S, Cuthbertson S: Anti-diabetic and hypoglycaemic effects of Momordica charantia (bitter melon): a mini review. Br J Nutr 2009;102:1703-1708.
9. Klomann SD, Mueller AS, Pallauf J, Krawinkel MB: Antidiabetic effects of bitter gourd extracts in insulin-resistant db/db mice. Br J Nutr 2010;104:1613-1620.
10. Shih CC, Lin CH, Lin WL, Wu JB: Momordica charantia extract on insulin resistance and the skeletal muscle GLUT4 protein in fructose-fed rats. J Ethnopharmacol 2009;123:82-90.
11. Chaturvedi P, George S: Momordica charantia maintains normal glucose levels and lipid profiles and prevents oxidative stress in diabetic rats subjected to chronic sucrose load. J Med Food 2010;13:520-527.
12. Gadang V, Gilbert W, Hettiararchchy N, Horax R, Katwa L, Devareddy L: Dietary bitter melon seed increases peroxisome proliferator-activated receptor-c gene expression in adipose tissue, down-regulates the nuclear factor-jB expression, and alleviates the symptoms associated with metabolic syndrome. J Med Food 2011;14:86-93.
13. Wong JH, Wang HX, Ng TB: Marmorin, a new ribosome inactivating protein with antiproliferative and HIV-1 reverse transcriptase inhibitory activities from the mushroom Hypsizigus marmoreus. Appl Microbiol Biotechnol 2008;81:669-674.
14. Xiong SD, Yu K, Liu XH, Yin LH, Kirschenbaum A, Yao S, Narla G, DiFeo A, Wu JB, Yuan Y, Ho SM, Lam YW, Levine AC: Ribosome-inactivating proteins isolated from dietary bitter melon induce apoptosis and inhibit histone deacetylase-1 selectively in premalignant and malignant prostate cancer cells. Int J Cancer 2009;125:774-782.
15. Puri M, Kaur I, Kanwar RK, Gupta RC, Chauhan A, Kanwar JR: Ribosome inactivating proteins (RIPs) from Momordica charantia for anti viral therapy. Curr Mol Med 2009;9:1080-1094.
16. Pitchakarn P, Ogawa K, Suzuki S, Takahashi S, Asamoto M, Chewonarin T, Limtrakul P, Shirai T: Momordica charantia leaf extract suppresses rat prostate cancer progression in vitro and in vivo. Cancer Sci 2010;101:2234-2240.
17. Nagasawa H, Watanabe K, Inatomi H: Effects of bitter melon (Momordica charantia L.) or ginger rhizome (Zingiber officinale Rosc) on spontaneous mammary tumorigenesis in SHN mice. Am J Chin Med 2002;30:195-205.
18. Grossmann ME, Mizuno NK, Dammen ML, Schuster T, Ray A, Cleary MP: Eleostearic acid inhibits breast cancer proliferation by means of an oxidation-dependent mechanism. Cancer Prev Res (Phila) 2009;2:879-886.
19. Ray RB, Raychoudhuri A, Steele R, Nerurkar P: Bitter melon (Momordica charantia) extract inhibits breast cancer cell proliferation by modulating cell cycle regulatory genes and promotes apoptosis. Cancer Res 2010;70:1925-1931.
20. Chiampanichayakul S, Kataoka K, Arimochi H, Thumvijit S, Kuwahara T, Nakayama H, Vinitketkumnuen U, Ohnishi Y: Inhibitory effects of bitter melon (Momordica charantia Linn.) on bacterial mutagenesis and aberrant crypt focus formation in the rat colon. J Med Invest 2001;48:88-96.
21. Kohno H, Yasui Y, Suzuki R, Hosokawa M, Miyashita K, Tanaka T: Dietary seed oil rich in conjugated linolenic acid from bitter melon inhibits azoxymethane-induced rat colon carcinogenesis through elevation of colonic PPARgamma expression and alteration of lipid composition. Int J Cancer 2004;110:896-901.
22. Yasui Y, Hosokawa M, Sahara T, Suzuki R, Ohgiya S, Kohno H, Tanaka T, Miyashita K: Bitter gourd seed fatty acid rich in 9c,11t,13t-conjugated linolenic acid induces apoptosis and upregulates the GADD45, p53 and PPARgamma in human colon cancer Caco-2 cells. Prostaglandins Leukot Essent Fatty Acids 2005;73:113-119.
23. Khan SA: Bitter gourd (Momordica charantia): a potential mechanism in anti-carcinogenesis of colon. World J Gastroenterol 2007;13:1761-1762.
24. Adams LS, Phung S, Yee N, Seeram NP, Li L, Chen S: Blueberry phytochemicals inhibit growth and metastatic potential of MDAMB- 231 breast cancer cells through modulation of the phosphatidylinositol 3-kinase pathway. Cancer Res 2010;70: 3594-3605.
25. Yang WH, Gutierrez NM, Wang L, Ellsworth BS, Wang CM: Synergistic activation of the Mc2r promoter by FOXL2 and NR5A1 in mice. Biol Reprod 2010;83:842-851.
26. Ragazzon B, Assié G, Bertherat J: Transcriptome analysis of adrenocortical cancers: from molecular classification to the identification of new treatments. Endocr Relat Cancer 2011;18: R15-R27.
27. Mannelli M, Colagrande S, Valeri A, Parenti G: Incidental and metastatic adrenal masses. Semin Oncol 2010;37:649-661.
28. Denmeade SR, Isaacs JT: Programmed cell death (apoptosis) and cancer chemotherapy. Cancer Control 2996;3:303-309.
29. Nerurkar PV, Lee YK, Motosue M, Adeli K, Nerurkar VR: Momordica charantia (bitter melon) reduces plasma apolipoprotein B-100 and increases hepatic insulin receptor substrate and phosphoinositide-3 kinase interactions. Br J Nutr 2008;100: 751-759.
30. Kim AC, Barlaskar FM, Heaton JH, Else T, Kelly VR, Krill KT, Scheys JO, Simon DP, Trovato A, Yang WH, Hammer GD: In search of adrenocortical stem and progenitor cells. Endocr Rev 2009;30:241-263.
31. Hoeflich A, Bielohuby M: Mechanisms of adrenal gland growth: signal integration by extracellular signal regulated kinases1/2. J Mol Endocrinol 2009;42:191-203.
32. Kilianova Z, Basora N, Kilian P, Payet MD, Gallo-Payet N: Human melanocortin receptor 2 expression and functionality: effects of protein kinase A and protein kinase C on desensitization and internalization. Endocrinology 2006;147:2325-2337.
33. Forti FL, Dias MH, Armelin HA: ACTH receptor: ectopic expression, activity and signaling. Mol Cell Biochem 2006;293: 147-160.
34. Kurmasheva RT, Dudkin L, Billups C, Debelenko LV, Morton CL, Houghton PJ: The insulin-like growth factor-1 receptortargeting antibody, CP-751,871, suppresses tumor-derived VEGF and synergizes with rapamycin in models of childhood sarcoma. Cancer Res 2009;69:7662-7671.
35. Ramakrishnan V, Timm M, Haug JL, Kimlinger TK, Wellik LE, Witzig TE, Rajkumar SV, Adjei AA, Kumar S: Sorafenib, a dual Raf kinase/vascular endothelial growth factor receptor inhibitor has significant anti-myeloma activity and synergizes with common anti-myeloma drugs. Oncogene 2010;29:1190-1202.
36. Zhang H, Fagan DH, Zeng X, Freeman KT, Sachdev D, Yee D: Inhibition of cancer cell proliferation and metastasis by insulin receptor downregulation. Oncogene 2010;29:2517-2527.
37. Britvin TA, Kazantseva IA, Kalinin AP, Kushlinskii NE: Vascular endothelium growth factor in the sera of patients with adrenal tumors. Bull Exp Biol Med 2005;140:228-230.
38. Luconi M, Mangoni M, Gelmini S, Poli G, Nesi G, Francalanci M, Pratesi N, Cantini G, Lombardi A, Pepi M, Ercolino T, Serio M, Orlando C, Mannelli M: Rosiglitazone impairs proliferation of human adrenocortical cancer: preclinical study in a xenograft mouse model. Endocr Relat Cancer 2010;17:169-177.
39. Soon PS, Gill AJ, Benn DE, Clarkson A, Robinson BG, McDonald KL, Sidhu SB: Microarray gene expression and immunohistochemistry analyses of adrenocortical tumors identify IGF2 and Ki-67 as useful in differentiating carcinomas from adenomas. Endocr Relat Cancer 2009;16:573-583.
40. Else T, Trovato A, Kim AC, Wu Y, Ferguson DO, Kuick RD, Lucas PC, Hammer GD: Genetic p53 deficiency partially rescues the adrenocortical dysplasia phenotype at the expense of increased tumorigenesis. Cancer Cell 2009;15:465-476.
41. Ragazzon B, Libé R, Gaujoux S, Assié G, Fratticci A, Launay P, Clauser E, Bertagna X, Tissier F, de Reyniès A, Bertherat J: Transcriptome analysis reveals that p53 and b-catenin alterations occur in a group of aggressive adrenocortical cancers. Cancer Res 2010;70:8276-8281.
42. Haluska P, Worden F, Olmos D, Yin D, Schteingart D, Batzel GN, Paccagnella ML, de Bono JS, Gualberto A, Hammer GD: Safety, tolerability, and pharmacokinetics of the anti-IGF-1R monoclonal antibody figitumumab in patients with refractory adrenocortical carcinoma. Cancer Chemother Pharmacol 2010; 65:765-773.
43. Pitchakarn P, Suzuki S, Ogawa K, Pompimon W, Takahashi S, Asamoto M, Limtrakul P, Shirai T: Induction of G1 arrest and apoptosis in androgen-dependent human prostate cancer by Kuguacin J, a triterpenoid from Momordica charantia leaf. Cancer Lett 2011;306:142-150.